ASCIA Action Plans for Anaphylaxis
The following 2018 versions of ASCIA Action Plans are the latest versions and are valid for use throughout 2019, until the 'due for review date' on the plan. A 2017 version is also valid if the 'due for review date' is in 2018 or later.
ASCIA Action Plans have been developed as an easy to follow, single page document to assist in emergency treatment of anaphylaxis. The plans are medical documents that can be completed online and saved as PDFs, by the treating medical or nurse practitioner. After typing patient details into the text fields, "save as" and save with a new name (e.g. patient name).
 |
ASCIA Action Plan for Anaphylaxis (personal) for use with EpiPen 2018
|
 |
ASCIA Action Plan for Anaphylaxis (personal) for use with any brand of adrenaline autoinjector 2018
|
|
|
ASCIA Action Plan for Allergic Reactions (personal) for use when no adrenaline autoinjector has been prescribed 2018
|
The following 2018 version of the ASCIA Action Plan (general) can be used as a poster or in first aid kits
 |
ASCIA Action Plan for Anaphylaxis (general) for use with EpiPen 2018
|
 |
ASCIA Action Plan for Anaphylaxis (general) for use with any brand of adrenaline autoinjector 2018
|
Important information:
1. ASCIA Action Plans should be reviewed and reissued when patients are reassessed by their doctor, and each time they obtain a new adrenaline autoinjector prescription, which is approximately every 12 to 18 months. If there are no changes in diagnosis or management the medical information on the ASCIA Action Plan may not need to be updated. However, if the patient is a child, the photo should be updated each time, so they can be easily identified.
2. ASCIA Action Plans for Anaphylaxis can be used for individuals with food and insect allergies (ASCIA Action Plans specific for Insect Allergy were discontinued in March 2011).
3. ASCIA Action Plans for Anaphylaxis include instructions on how to use an adrenaline autoinjector and should therefore always be stored with the autoinjector.
4. Adrenaline autoinjectors contain a single, fixed dose of adrenaline and are designed to be used by anyone (medical training is not required), including friends, teacher, childcare worker, parents or patients (if they are not too unwell or too young).
5. It is generally recommended that individuals who carry an adrenaline autoinjector should also wear a medical identification/emergency response emblem or other medical identification.
6. ASCIA Action Plans should be used as part of a comprehensive anaphylaxis management plan that includes:
- Age appropriate education of allergic individuals and their peers or colleagues (patient support organisations have a range of resources to help educate children)
- Training in the recognition and management of allergic reactions (ASCIA has a range of anaphylaxis e-training courses that can be used for this purpose)
- Development of strategies to reduce the risk of accidental exposure (refer to ASCIA Guidelines for Anaphylaxis Prevention and patient support organisations)
- An emergency response plan for when exposure does occur (ASCIA Action Plans for Anaphylaxis should be used for this purpose).
Content updated April 2019
